Upstream Bio, Inc. (NASDAQ:UPB) Receives Consensus Rating of “Hold” from Brokerages

Upstream Bio, Inc. (NASDAQ:UPB) has earned a consensus recommendation of “Hold” from the seven ratings firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $29.6667.

A number of research analysts have issued reports on UPB shares. Weiss Ratings upgraded Upstream Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, August 17th. HC Wainwright reissued a “buy” rating and set a $36.00 price target on shares of Upstream Bio in a report on Wednesday, September 2nd. JPMorgan Chase & Co. lifted their price objective on shares of Upstream Bio from $8.00 to $9.00 and gave the company a “neutral” rating in a research note on Friday, August 14th. Truist Financial decreased their target price on shares of Upstream Bio to $25.00 and set a “buy” rating for the company in a research report on Tuesday, August 11th. Finally, Wall Street Zen cut shares of Upstream Bio from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Public Employees Retirement System of Ohio acquired a new position in shares of Upstream Bio during the second quarter valued at approximately $33,000. Persistent Asset Partners Ltd acquired a new stake in Upstream Bio in the second quarter worth approximately $34,000. The Manufacturers Life Insurance Company boosted its stake in Upstream Bio by 51.2% during the 1st quarter. The Manufacturers Life Insurance Company now owns 15,338 shares of the company’s stock valued at $138,000 after purchasing an additional 5,191 shares in the last quarter. ProShare Advisors LLC bought a new position in Upstream Bio during the 4th quarter valued at $227,000. Finally, Hsbc Holdings PLC acquired a new position in shares of Upstream Bio during the 2nd quarter valued at $78,000.

Upstream Bio Trading Up 0.6%

UPB opened at $5.34 on Friday. The business’s 50 day moving average is $6.58 and its 200-day moving average is $7.73. The stock has a market cap of $292.47 million, a PE ratio of -1.84 and a beta of 1.28. Upstream Bio has a twelve month low of $5.21 and a twelve month high of $33.68.

Upstream Bio (NASDAQ:UPB) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.01. Upstream Bio had a negative return on equity of 48.40% and a negative net margin of 4,955.67%.The business had revenue of $0.77 million during the quarter, compared to analyst estimates of $0.56 million. As a group, analysts forecast that Upstream Bio will post -2.84 EPS for the current year.

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for inflammatory and immune-mediated diseases. The company’s research is centered on targeting biological pathways involved in chronic inflammation, with the goal of addressing conditions that may not be adequately controlled by existing therapies.

Upstream Bio’s lead product candidate is verekitug, a monoclonal antibody designed to block thymic stromal lymphopoietin (TSLP), an epithelial-cell-derived cytokine that plays a role in initiating and sustaining allergic and inflammatory responses.